COMPASS Pathways plc (NASDAQ:CMPS) Receives $21.83 Average Target Price from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have earned an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have covered the stock in the last year is $20.20.

CMPS has been the subject of several recent research reports. Stifel Nicolaus began coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price for the company. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, March 28th.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $2.79 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a one year low of $2.69 and a one year high of $10.31. The firm has a market capitalization of $258.56 million, a P/E ratio of -1.27 and a beta of 2.29. The company’s fifty day moving average is $3.83 and its two-hundred day moving average is $4.64.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Several large investors have recently made changes to their positions in CMPS. China Universal Asset Management Co. Ltd. purchased a new stake in COMPASS Pathways during the 4th quarter worth $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth about $43,000. Flagship Harbor Advisors LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth about $43,000. Conservest Capital Advisors Inc. grew its stake in shares of COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares in the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in COMPASS Pathways during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.